Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Modafinil | Phenibut | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 100-200 mg once daily (for educational context only — prescription medication in most jurisdictions) | 250-750 mg as needed, maximum 1-2 times per week (for educational context — carries significant dependence risk) |
| Timing | Early morning to avoid insomnia; 1 hour before desired peak alertness. With or without food (food slows absorption by ~1 hour but does not reduce bioavailability). Half-life is approximately 12-15 hours. | On an empty stomach (food significantly reduces absorption). Onset 2-4 hours. Effects last 4-8 hours with residual effects up to 24 hours. Half-life approximately 5.3 hours. |
| Cycle Duration | Not typically cycled in clinical use. Some off-label users cycle to maintain sensitivity (5 days on, 2 off; or as-needed use). | STRICTLY intermittent use only — maximum 1-2 times per week. NEVER use daily for more than 1 week. Tolerance develops within days, leading to dose escalation and dependence. |
| Evidence Level | strong_human | moderate_human |
Atypical eugeroic (wakefulness-promoting agent) that primarily inhibits the dopamine transporter (DAT), increasing extracellular dopamine in the prefrontal cortex and nucleus accumbens. This primary action cascades through multiple systems: indirect activation of orexinergic neurons in the lateral hypothalamus via potentiation of glutamatergic transmission; downstream stimulation of histaminergic neurons in the tuberomammillary nucleus (via orexin-mediated disinhibition of GABAergic inputs); and enhancement of norepinephrine release in the locus coeruleus. The net effect is broad-spectrum arousal without the peripheral sympathomimetic effects of classical stimulants.
100-200 mg once daily (for educational context only — prescription medication in most jurisdictions)
Early morning to avoid insomnia; 1 hour before desired peak alertness. With or without food (food slows absorption by ~1 hour but does not reduce bioavailability). Half-life is approximately 12-15 hours.
Not typically cycled in clinical use. Some off-label users cycle to maintain sensitivity (5 days on, 2 off; or as-needed use).
Beta-phenyl derivative of GABA that crosses the blood-brain barrier (unlike GABA itself) due to the addition of a phenyl ring. Acts as a full agonist at GABA-B receptors with 30-68x lower affinity than baclofen, requiring correspondingly higher doses. Also binds to and blocks alpha-2-delta subunit-containing voltage-dependent calcium channels (VDCCs), making it a gabapentinoid similar to gabapentin and pregabalin. At low concentrations, mildly increases dopamine levels in the brain, providing stimulatory and nootropic effects alongside anxiolysis. Weak agonist activity at GABA-A receptors at higher doses.
250-750 mg as needed, maximum 1-2 times per week (for educational context — carries significant dependence risk)
On an empty stomach (food significantly reduces absorption). Onset 2-4 hours. Effects last 4-8 hours with residual effects up to 24 hours. Half-life approximately 5.3 hours.
STRICTLY intermittent use only — maximum 1-2 times per week. NEVER use daily for more than 1 week. Tolerance develops within days, leading to dose escalation and dependence.
Fast buy links (we may earn a small commission at no extra cost).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →